GENETIC TESTING AND MOLECULAR BIOMARKERS Volume 19, Number 7, 2015 ª Mary Ann Liebert, Inc. Pp. 366–371 DOI: 10.1089/gtmb.2015.0029

Association Between BDNF Gene Polymorphisms and Attention Deficit Hyperactivity Disorder in Korean Children Ho Jang Kwon,1,2 Mina Ha,1,2 Han Jun Jin,1,3 Jung Keun Hyun,4,5 Se Hoon Shim,6 Ki Chung Paik,1,7 Woo Sung Park,8 and Myung Ho Lim1,9

Background: Attention deficit hyperactivity disorder (ADHD) is a common childhood neuropsychiatric disorder characterized by behavioral problems such as attention deficit, hyperactivity, and impulsivity. The brain-derived neurotrophic factor (BDNF) is the most abundant neurotrophin in the brain. Aims: The aim of the present study was to investigate the association between the genotype and alleles for the BDNF gene in Korean children with ADHD. Methods: The sample consisted of 180 ADHD children and 159 control children. We diagnosed ADHD according to the DSM-IV. ADHD symptoms were evaluated with Conners’ Parent Rating Scales and Dupaul Parent ADHD Rating Scales. Blood samples were taken from the 339 subjects, DNA was extracted from blood lymphocytes, and polymerase chain reaction was performed for BDNF rs6265, rs11030101, rs10835210, rs7103873, and rs2030324 polymorphisms. Alleles and genotype frequencies were compared using the Chi-square test. We compared the allele and genotype frequencies of the BDNF gene polymorphism in the ADHD and control groups. Results: This study showed that there was a significant correlation among the allele frequencies of the rs11030101 and rs10835210 single nucleotide polymorphisms (SNPs) (odds ratio = 0.61, 95% confidence interval = 0.39–0.96, p = 0.034), but the final conclusions are not definite. Follow-up studies with larger patient or pure subgroups are expected. These results suggest that the BDNF allelic structure may impact ADHD symptoms.

Introduction

A

ttention deficit hyperactivity disorder (ADHD) is a common childhood neuropsychiatric disorder characterized by behavioral problems such as attention deficit, hyperactivity, and impulsivity (American Psychiatric Association Committee on Nomenclature and Statistics, 1994). It has a prevalence of 2–7.6% among children of school age in Korea (Cho and Shin, 1994; Kim et al., 1999). Family studies reported that ADHD showed a heredity as high as 80–90% (Faraone et al., 2001), and molecular genetic studies are actively carried out accordingly. The brain-derived neurotrophic factor (BDNF) is the most abundant neurotrophin in the brain. It enhances the growth and maintenance of several neuronal systems, serves as a neurotransmitter modulator, and participates in mechanisms

of neuronal plasticity, such as long-term potentiation and learning (Theonen et al., 1995). The evidence from neurobiological and pharmacological research supports the role of neurotrophic factors in ADHD pathogenesis. Given that ADHD is a neurodevelopmental disorder, neurotrophic factors supporting neuronal survival, proliferation, and differentiation, as well as survival and synaptic plasticity in the central nervous system might be involved in ADHD susceptibility. Among neurotrophic factors, BDNF, which is critical for the survival and differentiation of midbrain dopaminergic neurons and the phenotypic differentiation of locus ceruleus noradrenergic neurons, has been a focus (Hyman et al., 1991; Huang and Reichardt, 2001; Traver et al., 2006). The BDNF gene is expressed in the mesolimbic dopaminergic system, the prefrontal cortex, the limbic system, and the cerebellum, which have been implicated in ADHD pathogenesis

1

Environmental Health Center, Dankook Medical Hospital, Cheonan, South Korea. Department of Preventive Medicine, College of Medicine, Dankook University, Cheonan, South Korea. 3 Department of Nanobiotics, College of Natural Science, Dankook University, Cheonan, South Korea. 4 Department of Rehabilitation Medicine, College of Medicine, Dankook University, Cheonan, South Korea. 5 Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan, South Korea. 6 Department of Psychiatry, College of Medicine, Soonchunhyang University, Cheonan, South Korea. Departments of 7Psychiatry and 8Pediatrics, College of Medicine, Dankook University, Cheonan, South Korea. 9 Department of Psychology, College of Public Welfare, Dankook University, Cheonan, South Korea. 2

366

BDNF POLYMORPHISMS AND ADHD

367

(Huang and Reichardt, 2001). Moreover, BDNF mediates psychostimulant-induced neuroadaptations and locomotor activity through the dopaminergic, serotoninergic, and noradrenergic neurotransmitter systems (Ribase´s et al., 2008). A Korean study reported a positive correlation between plasma BDNF levels and severity of omission errors on the continuous performance test in patients with ADHD (Shim et al., 2008). The previous studies on BDNF gene polymorphism and ADHD had conflicting results. One study found evidence for preferential transmission of the Val allele (rs6265) in a familybased sample (Kent et al., 2005). Another case–control (Aureli et al., 2010) association study and a haplotype association analysis (Lanktree et al., 2008) also found that the Val allele was significantly associated with ADHD. However, others could not replicate the results (Friedel et al., 2005; Lee et al., 2007; Schimmelmann et al., 2007; Xu et al., 2007; Ribase´s et al., 2008; Cho et al., 2010; Tzang et al., 2013) (Table 1). The aim of the present study was to investigate the association between the genetic type and alleles for the BDNF gene in Korean children with ADHD. Materials and Methods Subjects

A questionnaire was conducted with about 16,000 elementary school students in a city whose population is about 500,000 from September 2008 to August 2010. An interview was performed randomly with the children whose Korean version of the Dupaul Attention Deficit Hyperactivity Disorder rating scale (K-ARS) (Kim et al., 2002) score was 19 or higher, and 180 ADHD children who consented to the genetic study were selected. For the control group, 159 children in the same area were selected by matching the sex and age of the subjects in the patient group. For both the patient and control groups, a clinical evaluation and the DSM-IV diagnosis (American Psychiatric Association Committee on Nomenclature and Statistics, 1994) were performed by a child psychiatrist. The number of ADHD children was 180, including 132 boys (73.3%) and 48 girls (26.7%), and the mean age was 8.67 – 0.84. The number of children in the control group was

159, including 100 boys (62.9%) and 59 girls (37.1%), and the mean age was 8.59 – 0.79. There was no significant difference in the sex and age between the two groups (Table 2). Subjects were excluded from the study if there was any evidence of conduct disorder, mood disorder, anxiety disorder, Tourette’s disorder, pervasive development disorder, mental retardation (IQ < 70), and neurological disorders, including epilepsy. None of the children who participated in the study had ever undergone drug treatment before the evaluation. Informed consent was obtained before study entry. The study was also approved by the hospital ethics committee. None of the children was taking psychostimulants at the time of the study. On the day of visiting the hospital, the child psychiatrist performed a clinical interview as well as Kovac’s Children’s Depression Inventory (Kovacs, 1983), State Anxiety Inventory (SAIC), Trait Anxiety Inventory (TAIC) (Cho et al., 1989), Dupaul Attention Deficit Hyperactivity Disorder rating scales (K-ARS) (Kim et al., 2002), computerized ADHD diagnostic system (ADS) (Shin et al., 2000), and completed a questionnaire survey regarding the pregnancy, infancy, developmental history, and anamnesis of the children with their parents. Subjects were included from our sample if they had a score over two standard deviations from the norm on the tests for ADS (T-score > 70). ADHD had a lot of comorbid disorders, such as depressive disorder and anxiety disorder. Therefore, we excluded children with a high score of depressive symptoms and anxiety symptoms. Subjects with high anxiety scores (a Spielberger Trait/State Anxiety Scale Score > 47/49) on the Korean version of the Spielberger Trait/State Anxiety Scale for children were excluded, and subjects with high depression scores (Kovacs Depression Inventory Score > 29) on Kovacs Depression Inventory for children were also excluded. In addition, a professional clinical psychologist performed a comprehensive psychological test, including an intelligence test, on each subject. DNA extraction and genotyping

DNA was extracted from leukocytes using a commercial DNA extraction kit, the Wizard Genomic DNA Purification

Table 1. The Previous Studies of ADHD with BDNF Gene Study reference

Methods

Population

rs6265 (Val66Met) rs6265 (Val66Met) rs6265, rs11030104, rs2049046 rs6265

Family based Case/control Family based

341 families 96 and 88 266 families

Positive result Negative result Negative result

Family based

Negative result

Schimmelmann et al. (2007) Ribase´s et al. (2008) Lanktree et al. (2008) Cho et al. (2010)

rs6265

Family based

180 and 212 proband 294 families

rs1491850, rs11030096 rs6265 rs11030101, rs6265, rs16917204

Aureli et al. (2010) Tzang et al. (2013)

rs6265 rs1519480, rs6265, rs7940188, rs7103411, rs7103873

Case/control Family based Case/control and familybased study Case/control Family based

Kent et al. (2005) Friedel et al. (2005) Lee et al. (2007) Xu et al. (2007)

Polymorphisms

325 and 539 80 trios 202 and 159; 151 trios — 285 families

ADHD, attention deficit hyperactivity disorder; BDNF, brain-derived neurotrophic factor.

Study result

Negative result Negative result Positive result Negative result, but a positive result in only girl with rs11030101 Positive result Negative result

368

KWON ET AL.

Table 2. Epidemiological Characteristics Between the ADHD Group and the Control Group Rating scale

ADHD Control group (n = 180) group (n = 159) F or mean – SD mean – SD w2 p-Value

8.67 – 0.84 Agea Sex (n, %)b Female 48 (26.7%) Male 132 (73.3%)

8.59 – 0.79

0.06

0.813

59 (37.1%) 100 (62.9%)

3.79

0.052

These data represent mean – SD, by independent t-test,a or n (%), by w2 test,b significant p-value < 0.05.

Kit (Promega, Madison, WI). The BDNF single-nucleotide polymorphism (SNP) was genotyped by polymerase chain reaction according to the protocol described by studies (Cho et al., 2010). We selected the following five SNPs in the BDNF gene (NM170733 and NR002832): rs6265 (axon 1), rs11030101 (axon 1), rs10835210 (intron 1), rs7103873 (3¢flanking region), and rs2030324 (intron 1) that were genotyped by Illumina, Inc. (San Diego, CA) through the use of their Integrated Bead Array System (Table 3). We supplied Illumina with barcoded DNA microtiter plates containing the DNA quantified with Pico Green to be at 100 ng/mL and Illumina delivered genotypes with quality scores calculated by proprietary Illumina algorithms. Statistical analysis

We performed independent t-tests for age, chi-square (v2) tests for sex, and v2 tests to compare the results of the control group and the ADHD group through the frequency of the genotypes and alleles. SPSS PC software (version 15.0) was used for the statistical analysis, and the significance level was set to the p-value being less than 0.05. The calculation revealed that a sample size of 210 subjects is required to obtain a power that is 95% or higher in the v2 test between the control group and the patient group. Our study was conducted with 339 subjects and the power was 97.41%. This indicates that the association of the BDNF gene polymorphism and ADHD can be sufficiently accounted for by the results in this study. However, we performed the power program analysis for the v2 test with 339 subjects and the result showed that the effect size was 0.46 (moderate level). Results

any psychostimulant in advance. There was no difference in the age (F = 0.06, p = 0.813) and sex (F = 3.79, p = 0.052) between the control group and the ADHD children group (Table 2). Comparison of the frequency of the genotypes and alleles with genetic polymorphism of BDNF between the control group and the ADHD group

The BDNF–rs6265 genotypes of the 159 subjects in the control group and the 180 subjects in the ADHD group were G/G (28.48%: 29.78%), G/A (51.90%: 46.07%), and A/A (19.62%: 24.16%), and there was not a significant difference in the frequency between the two groups (v2 = 0.64, df = 2, p = 0.522) (Table 4). The BDNF–rs11030101 genotypes of the 159 subjects in the control group and the 180 subjects in the ADHD group were A/A (40.51%: 50.00%), A/T (51.27%: 38.76%), and T/T (8.23%: 11.24%), and there was a significant difference in the frequency between the two groups (v2 = - 2.11, df = 2, p = 0.034) (Table 4). The BDNF–rs10835210 genotypes of the 159 subjects in the control group and the 180 subjects in the ADHD group were C/C (40.51%: 50.00%), C/A (51.27%: 38.76%), and A/A (8.23%: 11.24%), and there was a significant difference in the frequency between the two groups (v2 = - 2.11, df = 2, p = 0.034) (Table 4). The BDNF– rs7103873 genotypes of the 159 subjects in the control group and the 180 subjects in the ADHD group were G/G (24.68%: 26.97%), G/C (52.53%: 48.88%), and C/C (22.78%: 24.16%), and there was not a significant difference in the frequency between the two groups (v2 = - 0.61, df = 2, p = 0.544) (Table 4). The BDNF–rs2030324 genotypes of the 159 subjects in the control group and the 180 subjects in the ADHD group were T/T (24.05%: 26.97%), T/C (53.16%: 48.88%), and C/C (22.78%: 24.16%), and there was not a significant difference in the frequency between the two groups (v2 = - 0.75, df = 2, p = 0.455) (Table 4). Odds ratio of the genotypes and alleles with genetic polymorphism of BDNF between the control group and the ADHD group

The odds ratio (OR) of the BDNF–rs11030101 and rs10835210 genotypes was significant at 0.61 (confidence interval [CI]: 0.39–0.96, p = 0.034) and the OR of the –rs11030101 and rs10835210 alleles was not significant at 0.87 (CI: 0.63–1.20, p = 0.385) (Table 4).

Demographic characteristics of the subjects

Discussion

The subjects were a total of 339 children. The children in both the ADHD group and the control group had never taken

This study is a case–control study, in which the frequency of the genotypes and alleles of BDNF was compared between

Table 3. Single-Nucleotide Polymorphisms Considered in This Study SNP ID BDNF rs6265 rs11030101 rs10835210 rs7103873 rs2030324

Chromosome

Location

Position (coordinate)

Distance

11 11 11 11 11

UTR UTR Intron Flanking 3l Intron

27636491 27637319 27652485 27656892 27683490

128/93 26/31 - 934 - 965 - 3762

NCBI gene ID (Accession) is 2562 (NR002832 and NM170733). SNP, single-nucleotide polymorphism.

Alleles G/A A/T C/A G/C T/C

BDNF POLYMORPHISMS AND ADHD

369

Table 4. Multivariate Model for Genotype Distributions and Allele Frequencies in the ADHD Group and the Control Group Control Characteristics BDNF–rs6265 (G/A) Genotype GG GA AA Allele G A BDNF–rs11030101 (A/T) Genotype AA AT TT Allele A T BDNF–rs10835210 (C/A) Genotype CC CA AA Allele C A BDNF–rs7103873 (G/C) Genotype GG GC CC Allele G C BDNF–rs2030324 (T/C) Genotype TT TC CC Allele T C

ADHD

n

%

n

%

45 82 31

28.48 51.90 19.62

53 82 43

29.78 46.07 24.16

172 144

54.43 45.57

190 170

52.81 47.19

64 81 13

40.51 51.27 8.23

89 69 20

50.00 38.76 11.24

209 107

66.14 33.86

247 109

69.38 30.62

64 81 13

40.51 51.27 8.23

89 69 20

50.00 38.76 11.24

209 107

66.14 33.86

247 109

69.38 30.62

39 83 36

24.68 52.53 22.78

48 87 43

26.97 48.88 24.16

161 155

50.95 49.05

183 173

51.40 48.60

38 84 36

24.05 53.16 22.78

48 87 43

26.97 48.88 24.16

160 156

50.63 49.37

183 173

51.40 48.60

w2

OR

95% CI

0.85

0.51–1.40

0.64

0.522

1.07

0.79–1.44

0.42

0.672

0.61

0.39–0.96

- 2.11

0.034

0.87

0.63–1.20

- 0.87

0.385

0.61

0.39–0.96

- 2.11

0.034

0.87

0.63–1.20

- 0.87

0.385

0.85

0.51–1.43

- 0.61

0.544

0.98

0.73–1.33

- 0.12

0.910

0.82

0.49–1.38

- 0.75

0.455

0.97

0.72–1.31

- 0.20

0.840

p

These data represent n (%) by w2 test, significant p-value < 0.05. CI, confidence interval; OR, odds ratio.

the ADHD children and the control group in Korea. The correlation between the genotypes and alleles of one candidate BDNF SNP was investigated. This study showed that there was a significant correlation between the frequencies of the BDNF–rs11030101 and rs10835210 and ADHD. To our knowledge, this result is the first report on the association between the BDNF polymorphism and ADHD in Asia. In a study of Korean children, which is the only previous study about the female-specific association between ADHD and BDNF, Cho et al. (2010) reported the association between the rs11030101 genetic polymorphism of the BDNF gene and ADHD that was reported first in Korea. However, in this study, the correlation between ADHD and BDNF– rs11030101 and rs10835210 genetic polymorphism was found first. Combining the results about the correlation be-

tween the BDNF–rs11030101 and rs10835210 and ADHD, it can be understood that the failure of BDNF regulation may cause the pathogenesis of ADHD. Several lines of evidence suggest that BDNF plays a role in the etiology of ADHD. First, earlier studies demonstrated that BDNF plays a key role in the survival and differentiation of midbrain dopaminergic neurons in vivo (Hyman et al., 1991) and in vitro (Spina et al., 1992). Since the dysfunction in the midbrain system is crucial in ADHD pathogenesis (Solanto, 2002), a decreased midbrain BDNF activity may cause midbrain dopaminergic dysfunction and, therefore, resulting in ADHD. Second, psychostimulants, such as methylphenidate, are the agents commonly used in the treatment of ADHD. The classical action mechanism of psychostimulants involves enhancement of the release of dopamine and norepinephrine in the midbrain.

370

BDNF has been shown to modulate the release of dopamine through activation of TrkB receptors (Blochl and Sirrenberg, 1996) and has also been implicated in the release of dopamine as well as in dopamine-related behaviors induced by the psychostimulant, methamphetamine (Narita et al., 2003). Furthermore, psychostimulants and antidepressants are the agents commonly used for the treatment of ADHD, and both have been found to elevate central BDNF (Meredith et al., 2002). Third, earlier studies showed that BDNF heterozygous null mutants (Kernie et al., 2000) and BDNF conditional knockout mice (Rios et al., 2001) exhibit increased locomotor hyperactivity, which mimics fundamental behavioral characteristics of ADHD (Sagvolden et al., 2005). Fourth, reduced central serotonergic activity has been implicated in poor impulse regulation, which is a feature of ADHD in young children, adults, and animals (Lucki, 1998), and a subset of BDNF heterozygous mice demonstrate physiological disturbance in central serotonergic neurons linked with behavioral abnormalities, including increased aggressiveness. This suggests that endogenous BDNF may be critical for normal development and function of central serotonergic neurons (Lyons et al., 1999) and hence impulse regulation. The methodological limitations of this study are as follows: first, the number of subject children was small. The subjects of this study were 180 ADHD children and 159 children in the control group. Second, the covariance factors (i.e., the socioeconomic status, the educational level of parents, the regional differences) of ADHD could not be removed when the result of the study was analyzed. Besides, physical examination for ADHD was not performed. Third, we surveyed one city of the Republic of Korea, and our survey findings were therefore subject to selection bias of the methodology. Fourth, the results of this study may not be generalized for the cases of other racial or ethnic groups since the frequency of alleles can vary due to racial differences. The distribution of the allele frequency in the ADHD patient children and parent group in this study was also different from that of other countries. Fifth, only a few SNPs were investigated in this study among the many genes related with the various ADHD phenotypes. Although it is clear that not just one genetic factor causes the increased ADHD vulnerability, we did not consider the interaction with other risk factors. Despite the methodological limitations described before, this study has several advantages. First, the patient group and the control group had no difference in the frequency of sex and age. The prevalence of ADHD is higher among males and in adolescence; thus, the sex and age characteristics can have a great effect. Considering this, our study was evaluated by adjusting the age and sex of the patient group and the control group with each other. Second, this study used populationbased samples. Previous studies in Korea were hardly considered to represent the general population because the subjects were usually ADHD children who visited hospitals for their clinical symptoms. In this study, the subjects in the risk group were selected by the questionnaire survey from the whole population in a region, and the patient and control samples were obtained by random contact. Thus, the subjects in this study may be more appropriate to the characteristics of general population than those of the study performed with the patients who visited hospitals. Third, this study might have compared relatively homogenous groups that had the characteristics of Koreans, different from the studies conducted in

KWON ET AL.

other countries with subjects from various ethnic groups and nations. Fourth, both the patient group and control group in this study underwent clinical evaluation and DSM-IV diagnosis by child psychiatrists, applying the inclusion and exclusion criteria strictly, and thus the patient group was composed of pure ADHD-diagnosed subjects. We expect that different allele distribution results may be produced from future studies on the quantitative correlation of the ADHD performance in the pure ADHD group from which coexisting diseases are excluded; the patient group composed of only boys or girls, the subtype groups such as the hyperactivity dominant group and attention deficiency dominant group, and the drug response group. Acknowledgments

This work was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI13C0747) and was supported by the National Research Foundation of Korea Grant funded by the Korean Government (NRF-2013R1A1A4A01007101). Author Disclosure Statement

No competing financial interests exist. References

American Psychiatric Association Committee on Nomenclature and Statistics (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), Fourth Edition. Washington, DC: American Psychiatric Association Press. Aureli A, Del Beato T, Sebastiani P, et al. (2010) Attentiondeficit hyperactivity disorder and intellectual disability: a study of association with brain-derived neurotrophic factor gene polymorphisms. Int J Immunopathol Pharmacol 23:873–880. Blochl A, Sirrenberg C (1996) Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75Lntr receptors. J Biol Chem 271:21100–21107. Cho SC, Choi JS (1989) Development of Korean form of the state-trait anxiety inventory for children. J Seoul Psychiatry 14:150–157. Cho SC, Kim HW, Kim BN, et al. (2010) Gender-specific association of the brain-derived neurotrophic factor gene with attention-deficit/hyperactivity disorder. Psychiatry Investig 7:285–290. Cho SC, Shin YO (1994) Prevalence of disruptive behavior disorders. Korean J Child Adolesc Psychiatry 5:141–149. Faraone SV, Doyle AE (2001) The nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 10:299–316. Friedel S, Horro FF, Wermter AK, et al. (2005) Mutation screen of the brain derived neurotrophic factor gene (BDNF): identification of several genetic variants and association studies in patients with obesity, eating disorders, and attention-deficit/ hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 132:96–99. Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24:677–736. Hyman C, Hofer M, Barde YA, et al. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230–232.

BDNF POLYMORPHISMS AND ADHD

Kent L, Green E, Hawi Z, et al. (2005) Association of the paternally transmitted copy of common Valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene with susceptibility to ADHD. Mol Psychiatry 10:939–943. Kernie SG, Liebl DJ, Parada LF (2000) BDNF regulates eating behavior and locomotor activity in mice. EMBO J 19:1290– 1300. Kim JY, Ahn DH, Shin YJ (1999) An epidemiological study of attention deficit hyperactivity disorder and learning disabilities in a rural area. J Korean Neuropsychiatr Assoc 38:788–793. Kim YS, So YK, Noh JS, et al. (2002) The reliability and validity of Korean parent and teacher ADHD Rating Scale. J Korean Neuropsychiatr Assoc 41:283–289. Lanktree M, Squassina A, Krinsky M, et al. (2008) Association study of brain-derived neurotrophic factor (BDNF) and LIN-7 homolog (LIN-7) genes with adult attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B:945–951. Lee J, Laurin N, Crosbie J, et al. (2007) Association study of the brain-derived neurotropic factor (BDNF) gene in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 5:976–981. Lucki I (1998) The spectrumof behaviors influenced by serotonin. Biol Psychiatry 44:151–162. Lyons WE, Mamounas LA, Ricaurte GA, et al. (1999) Brainderived neurotrophic factor deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 96:15239–15244. Meredith G, Callen S, Scheuer D (2002) Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 949:218–227. Narita M, Aoki K, Takagi M, et al. (2003) Implication of brainderived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 119:767–775. Ribase´s M, Herva´s A, Ramos-Quiroga JA, et al. (2008) Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorder. Biol Psychiatry 63:935–945. Rios M, Fan G, Fekete C, et al. (2001) Conditional deletion of brainderived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol 15:1748–1757. Sagvolden T, Russell VA, Aase H, et al. (2005) Rodent models of attentiondeficit/hyperactivity disorder. Biol Psychiatry 57:1239–1247.

371

Schimmelmann BG, Friedel S, Dempfle A, et al. (2007) No evidence for preferential transmission of common valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor gene (BDNF) in ADHD. J Neural Transm 114:523–526. Shim SH, Hwangbo Y, Kwon YJ, et al. (2007) Increased levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 12:1824–1828. Shin MS, Cho SC, Chun SY, et al. (2000) A study of the development and standardization of ADHD diagnostic system. Korean J Child Adolesc Psychiatry 11:91–99. Solanto MV (2002) Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 130:65–71. Spina MB, Squinto SP, Miller J, et al. (1992) Brain derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 59:99–106. Theonen H (1995) Neurotrophins and neuronal plasticity. Science 270:593–598. Traver S, Marien M, Martin E, et al. (2006) The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMPdependent signaling pathway. Mol Pharmacol 70:30–40. Tzang RF, Hsu CD, Liou YJ, et al. (2013) Family-based association of the brain-derived neurotrophic factor gene in attentiondeficit hyperactivity disorder. Psychiatr Genet 23:177–178. Xu X, Mill J, Zhou K, et al. (2007) Family-based association study between brain-derived neurotrophic factor gene polymorphisms and attention deficit hyperactivity disorder in UK and Taiwanese samples. Am J Med Genet B Neuropsychiatr Genet 144:83–86.

Address correspondence to: Myung Ho Lim, MD, PhD Department of Psychology College of Public Welfare Dankook University Dandae-ro 119 Cheonan 330-714 South Korea E-mail: [email protected]

Association between BDNF gene polymorphisms and attention deficit hyperactivity disorder in Korean children.

Attention deficit hyperactivity disorder (ADHD) is a common childhood neuropsychiatric disorder characterized by behavioral problems such as attention...
137KB Sizes 0 Downloads 7 Views